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Summary
Background It was recently demonstrated that a significant number of
patients with common skin diseases across Europe are clinically depressed
and anxious. Studies have shown that physicians not trained as psychia-
trists underdiagnose depression. This has not been explored among
dermatologists.
Objectives To estimate the concordance between clinical assessment of depression
and anxiety by a dermatologist and assessment with the Hospital Anxiety and
Depression Scale (HADS).
Methods The study was an observational cross-sectional multicentre study of preva-
lent cases of skin diseases in 13 countries in Europe. Consecutive patients were
recruited in outpatient clinics and filled in questionnaires prior to clinical exami-
nation by a dermatologist who reported any diagnosis of skin disease and signs
of mood disorders.
Results Analysis of the 3635 consultations showed that the agreement between
dermatologist and HADS was poor to fair (lower than 04) for all diagnosis cate-
gories. The true-positive rate (represented by the percentage of dermatologists
recognizing signs of depression or anxiety in patients with depression or anxiety
as defined by a HADS value ≥ 11) was 440% for depression and 356% for anx-
iety. The true negative rate (represented by the percentage of dermatologists not
detecting signs of depression or anxiety in non-depressed or non-anxious
patients defined by HADS-value < 11) was 88.8% for depression and 85.7% for
anxiety.
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Conclusions Dermatologists in Europe tend to underestimate mood disorders. The
results suggest that further training for dermatologists to improve their skills in
diagnosing depression and anxiety might be appropriate. When present, the
psychological suffering of patients with dermatological conditions needs to be
addressed.
What’s already known about this topic?
• It has recently been demonstrated that patients with common skin diseases have
more depression and anxiety than controls.
• Research has shown that physicians who are not trained as psychiatrists miss
depression in their patients.
What does this study add?
• A large proportion of cases of depression in patients with skin disease are not diag-
nosed by dermatologists.
• These results indicate that further training for dermatologists to assess depression
and anxiety might be appropriate.
The Global Burden of Disease study shows that mood disor-
ders contribute substantially to global morbidity and are often
associated with physical conditions.1 The bilateral contribution
of depression to many chronic medical conditions is recog-
nized2 and has mostly been demonstrated in cross-sectional
studies.3 A recent mental health survey from the World Health
Organization carried out in 21 countries demonstrated that
major depression is widely undertreated worldwide.4 Many
people with mood disorders have no contact with mental
health services and are only managed by general practitioners
or other nonpsychiatric physicians.5 Depression management
can be challenging for physicians who are not trained as psy-
chiatrists and the symptomatology of depression is not always
obvious: a study in the U.S.A. showed that two-thirds of indi-
viduals with depression are undiagnosed in primary care.6
Many patients go ‘doctor-shopping’ because of their suffering,
which may lead to patients contributing a disproportionate
burden on the health system as a whole.
Furthermore, the recognition and the treatment of mood
disorders often influences the course of diseases, adherence to
treatment and the health behaviour of the patient.7 The evi-
dence of a strong association between physical conditions and
depression and anxiety is demonstrated in several meta-
analyses pointing out the need for an integrated care pro-
gramme including a more holistic approach to the patients’
suffering.8–11
Dermatologists regularly encounter mood disorders in their
clinical work. It was recently estimated that clinical depression
is seen in 10% of dermatological consultations and clinical
anxiety in 17% of consultations across European dermatologi-
cal outpatient clinics.12 The British Association of Dermatolo-
gists’ Psychodermatology Working Party estimated that 17%
of dermatological patients have psychological issues co-occur-
ring with their skin disease.13 This means that a substantial
proportion of patients attending dermatology clinics have
underlying psychological conditions and addressing the psy-
chopathology affecting dermatological patients should not be
neglected as they are part of the patients’ needs for care and,
thus, recovery. However, dermatologists are trained to diag-
nose skin diseases and are not necessarily trained in diagnos-
ing and treating psychiatric comorbidity that might be present
in their patients.
This study therefore aimed to estimate the concordance
between depression and anxiety assessed with the Hospital
Anxiety and Depression Scale (HADS) and clinical assessment
by a dermatologist using a brief questionnaire to record signs
of depression and anxiety.
Participants and methods
This was an observational cross-sectional multicentre study of
prevalent cases of skin diseases conducted by members of the
European Society for Dermatology and Psychiatry (ESDaP),
previously described in detail including population characteris-
tics.12 In summary, patients were recruited from dermatologi-
cal outpatient clinics in 13 European countries from
November 2011 to February 2013. The study protocol was
approved by the Regional Committee for Medical Research
Ethics in Norway and local ethical approval was also obtained
where necessary. The study was conducted in accordance with
the Declaration of Helsinki.
Settings
At the dermatological outpatient clinic of each centre, 250
consecutive patients were invited to participate in the study
on one or more random days until the desired number was
reached. All patients were fully informed about the study by a
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research assistant and signed a written consent form. The
inclusion criteria were: age over 18 years, being able to read
and write the local language and not having severe psychosis.
Each participant completed a questionnaire and returned it to
the consultant at the consultation.
Measures
The first part of the questionnaire recorded self-reported
sociodemographic variables.12
Depression and anxiety were assessed with the HADS. A
review of the validity of the HADS has been examined in 747
studies. These have demonstrated the solid psychometric prop-
erties of the instrument in assessing symptom severity and
‘caseness’ of anxiety disorders and depression in both somatic,
psychiatric, primary care patients and in the general popula-
tion.14,15 The questionnaire includes seven items assessing
anxiety, and seven for depression, each with four possible
answers (scored 0–3). For each dimension of anxiety and
depression a total score from 0 to 7 is considered normal,
from 8 to 10 a borderline case and from 11 to 21 indicating
a person with a clinical case in need of further examination or
treatment.
The HADS is available in the different languages relevant to
the study.14 For the present study the HADS values were
divided into two categories: ≤ 10, no or subclinical signs of
mental health distress and ≥ 11, individuals with a clinical case
in need of further examination or treatment. Each patient was
examined by a dermatologist who recorded the dermatological
diagnosis and the objective severity of the condition as ‘mild’,
‘moderate’ or ‘severe’. The presence of the following treated
comorbidities: cardiovascular disease, chronic respiratory dis-
ease, diabetes, rheumatological disease and other medical con-
ditions (such as cancer) were specified. In addition, the
dermatologists answered the following two questions: ‘Do you
see depressive signs in the patient?’ and ‘Do you see anxiety
signs in the patient?’. The possible answers were ‘yes’ or ‘no’.
Statistical analysis
The data were entered in a SPSS or an Excel database at each
site and analysed at the statistical centre at the Institute of
Medical Psychology, University of Giessen, Germany. SPSS ver-
sion 24 (IBM, Armonk, NY, U.S.A.) software was used to
analyse the data.
There were missing data for 250 patients in the case of anx-
iety and depression assessments by dermatologists, 102
patients for HADS-depression scores and 107 patients for
HADS-anxiety scores. Valid cases for measurement of concor-
dance were 3295 for depression and 3293 for anxiety.
Cross-tabulations were performed between clinical depres-
sion and anxiety assessed by the dermatologist, and the corre-
sponding HADS for the most common dermatological
diagnostic categories. Cohen’s kappa (j) is mostly used to cal-
culate agreement between two raters16, but kappa also can be
used to assess the concordance between alternative methods of
categorical assessment such as in our study. Kappa is a mea-
sure of the agreement between the two methods adjusted for
what would be expected by chance. To evaluate the strength
of concordance we used the recommendation of Fleiss:16
j < 040, poor to fair agreement; j between 041 and 080,
moderate to good; and j between 081 and 100, very good
agreement.
In addition we calculated the true-positive rate (or sensitivity;
depression and anxiety assessed by dermatologist/all patients
with HADS-depression and HADS-anxiety values ≥ 11); true-
negative rate (or specificity; no depression or anxiety assessed
by dermatologist/all patients with HADS-depression and HADS-
anxiety values < 11); false-positive rate (depression and anxiety
assessed by dermatologist/all patients with HADS-depression
and HADS-anxiety values < 11); and false-negative rate (no
depression and no anxiety assessed by dermatologist/all patients
with HADS-depression and HADS-anxiety values ≥ 11).
Results
Overall the results showed that there was a high concordance
between the dermatologists and the HADS questionnaire when
there was no depression (797%) and no anxiety (708%)
(Tables 1 and 2). However, overall the true-positive value was
440% for depression and 356% for anxiety and the false-
negative value was 56% for depression and 644% for anxiety
in the whole sample.
The dermatologists underestimated depression in 58% of
the consultations and anxiety in 112% of the consultations.
On the other hand, dermatologists overestimated depression
and anxiety in 100% and 118% of the consultations, respec-
tively.
Clinical assessment of depression was poorer for patients
with hand eczema (78%), psoriasis (88%) and leg ulcers
(86%); and the overestimation was higher for patients with leg
ulcers (200%), acne (127%) and atopic dermatitis (125%).
Clinical underestimation of anxiety was seen especially for
individuals with psoriasis (157%) and hand eczema (156%).
Overestimation of anxiety by the dermatologist was highest
for patients with leg ulcers (387%), infections of the skin
(161%) and acne (141%).
The agreement between the dermatologist and the patient-
assessed questionnaire (HADS) was poor to fair (lower than 04)
for all diagnose categories, which is the lowest category meaning
that the concordance is far from satisfactory. The agreement
(kappa coefficient) between doctor and patient was a bit higher
but still low for depression in patients with hand eczema
(0365), infections of the skin (0355) and leg ulcers (0347).
Discussion
Overall the agreement between clinician and patient assess-
ment of mood symptoms was poor, suggesting that mood
symptoms are under-recognized by dermatologists in a routine
care setting. The presence of mood disorders not only adds to
the suffering of patients, but is also relevant for clinicians to
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recognize and address when treating patients with skin dis-
eases because it could influence the course of the skin disease
and the adherence to treatment. To the best of our knowledge
this aspect of clinical dermatology has not yet been described
in the dermatological literature.
Discordance between clinician- and patient-assessed clinical
depression was found in several settings with a similar
approach. In a primary care setting among 231 participants,
two-thirds of the patients with depression were undiagnosed
by the practitioner. In this study they estimated the agreement
between the physician documentation of depression and the
self-reported Patient Health Questionnaire (PHQ-9) and the
Cohen’s kappa analysis showed only weak agreement.6 In pre-
vious studies the recognition of depressive symptoms in a
general practice setting has been reported in the range of
50%, although major depression has been reportedly recog-
nized at a rate of 64%.17–19
Oncologists could also be more astute assessors of depres-
sive symptoms: a study in patients with cancer by Gouveia
et al. indicates an oncologist’s sensitivity as 33% for individual
symptoms of depression.20 Taken together, these studies imply
that the problem of low recognition of depressive symptoms
in patients with somatic disease is not limited to dermatolo-
gists. Similar low recognition rates may be found using
patients’ self-assessment.21
It is noticeable that the underestimation of depression and
anxiety was particularly poor for patients with chronic derma-
tological conditions such as psoriasis, hand eczema and leg
ulcers. This points to the importance of focusing on patients
with longstanding conditions that do not get better. Here,
adherence problems might be present because of psychological
suffering that is not addressed, because it is not recognized.
The importance of using patient reported outcome measures
(PROMs) in clinical work was recently stressed in the New Eng-
land Journal of Medicine.22 In dermatology, quality of life measures
are the most widely and extensively used PROMs.23–25 A Dan-
ish study estimated the correlation between physician-assessed
morbidity of the patient and the self-reported Dermatology
Life Quality Index (DLQI) in 51 patients with dermatological
conditions. Physicians underestimated morbidity in patients
with more benign disease and overestimated morbidity in
patients with more aggressive disease, compared with the
patient’s assessment.26 A systematic review to determine
whether there is any correlation between DLQI scores and
psychiatric measure scores was performed. It concluded that
the DLQI correlated well with the depression domain of the
HADS score. This raises the possibility of the use of DLQI data
to alert clinicians to depression.25
For the purpose of this study the HADS is taken as the
gold standard, but the HADS is not free of errors when
detecting depression and anxiety. It has false-negative and
false-positive rates in addition to true-positive and true-
negative rates. So probably a small number of the HADS-
negative but physician-‘positive’ patients may have been
genuinely depressed or genuinely anxious. Nevertheless,
because of the high number of consultations the results are
probably clinically relevant.
A limitation of this study is that no detailed instructions
were given to the dermatologists on the assessment of depres-
sion or anxiety. Therefore, there could be a difference in basic
skills in assessing symptoms of depression and anxiety in the
different dermatologists. This could be because of differences
in training and a difference in interest in mental health
conditions.
Other limitations to our study have been described previ-
ously.12 Unfortunately, because of too small numbers of diag-
nostic categories within countries we were not able to
describe the concordance between dermatologist and patients,
country by country. We have therefore focused on the most
common diagnoses, as described previously.12
This study shows that dermatologists across Europe tend to
underestimate mood disorders in a significant group of
patients. The implications of these findings could be that fur-
ther training for dermatologists to improve their skills in rec-
ognizing depression and anxiety might be appropriate. The
findings support the need for psychodermatology services for
some patients with dermatological conditions and future
research should assess the benefits of a multidisciplinary
approach to treating patients with dermatological conditions
with psychological comorbidity.
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